PMID- 36672673
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230123
IS  - 2227-9059 (Print)
IS  - 2227-9059 (Electronic)
IS  - 2227-9059 (Linking)
VI  - 11
IP  - 1
DP  - 2023 Jan 9
TI  - Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine 
      in Cancer Patients-An Italian Single-Center Experience.
LID - 10.3390/biomedicines11010165 [doi]
LID - 165
AB  - Safety data regarding BNT162b2 in cancer patients (CPs) are scarce. Herein we 
      report the side effects (SEs), the adverse events (AEs), and the patient-reported 
      outcomes (PROs) following BNT162b2 administration in CPs treated at the San Luigi 
      Gonzaga University Hospital. All CPs who agreed to participate in our vaccination 
      campaign received BNT162b2 and were included in the descriptive analysis. An 
      anonymous questionnaire investigating the occurrence of SEs/AEs and PROs was 
      administered to the study population 21 days after the first dose. Pearson's 
      chi-squared test was used to estimate the risk of experiencing SEs/AEs according 
      to selected variables. A total of 997 patients were included in the study: 62.0% 
      had stage IV cancer, and 68.8% were receiving an active treatment, of whom 15.9% 
      were receiving immunotherapy. SEs/AEs were recorded in 37.1% of cases after the 
      first dose and in 48.5% of cases after the second dose. The most common SEs were 
      muscle pain/local rash (27.9% and 28%, after the first and second dose, 
      respectively). Patients older than 70 years showed lower risk of SEs/AEs, while 
      women showed a higher risk. Before receiving the vaccine, 18.2% of patients felt 
      fearful and/or insecure about the vaccination. After the first dose, 57.5% of 
      patients changed their feelings positively. Our data support the short-term 
      safety of BNT162b2 in CPs, regardless of disease stage and concurrent treatments. 
      Overall, the vaccination showed a positive impact on quality of life.
FAU - Persano, Irene
AU  - Persano I
AUID- ORCID: 0000-0003-2004-4644
AD  - Department of Oncology, University of Turin, San Luigi Gonzaga University 
      Hospital, 10043 Orbassano, Italy.
FAU - Cani, Massimiliano
AU  - Cani M
AUID- ORCID: 0000-0001-9608-4840
AD  - Department of Oncology, University of Turin, San Luigi Gonzaga University 
      Hospital, 10043 Orbassano, Italy.
FAU - Del Rio, Benedetta
AU  - Del Rio B
AUID- ORCID: 0000-0003-3053-6597
AD  - Department of Oncology, University of Turin, San Luigi Gonzaga University 
      Hospital, 10043 Orbassano, Italy.
FAU - Ferrari, Giorgia
AU  - Ferrari G
AUID- ORCID: 0000-0001-6424-7211
AD  - Department of Oncology, University of Turin, San Luigi Gonzaga University 
      Hospital, 10043 Orbassano, Italy.
FAU - Garbo, Edoardo
AU  - Garbo E
AUID- ORCID: 0000-0003-2394-9895
AD  - Department of Oncology, University of Turin, San Luigi Gonzaga University 
      Hospital, 10043 Orbassano, Italy.
FAU - Parlagreco, Elena
AU  - Parlagreco E
AUID- ORCID: 0000-0003-0368-755X
AD  - Department of Oncology, University of Turin, San Luigi Gonzaga University 
      Hospital, 10043 Orbassano, Italy.
FAU - Pisano, Chiara
AU  - Pisano C
AD  - Department of Oncology, University of Turin, San Luigi Gonzaga University 
      Hospital, 10043 Orbassano, Italy.
FAU - Cetoretta, Valeria
AU  - Cetoretta V
AD  - Department of Oncology, University of Turin, San Luigi Gonzaga University 
      Hospital, 10043 Orbassano, Italy.
FAU - Delcuratolo, Marco Donatello
AU  - Delcuratolo MD
AUID- ORCID: 0000-0003-3151-9166
AD  - Department of Oncology, University of Turin, San Luigi Gonzaga University 
      Hospital, 10043 Orbassano, Italy.
FAU - Turco, Fabio
AU  - Turco F
AUID- ORCID: 0000-0003-3111-7888
AD  - Department of Oncology, University of Turin, San Luigi Gonzaga University 
      Hospital, 10043 Orbassano, Italy.
FAU - Audisio, Alessandro
AU  - Audisio A
AUID- ORCID: 0000-0002-7101-2100
AD  - Department of Oncology, University of Turin, San Luigi Gonzaga University 
      Hospital, 10043 Orbassano, Italy.
FAU - Cecchi, Cristina
AU  - Cecchi C
AD  - Department of Oncology, University of Turin, San Luigi Gonzaga University 
      Hospital, 10043 Orbassano, Italy.
FAU - Leone, Gianmarco
AU  - Leone G
AD  - Department of Oncology, University of Turin, San Luigi Gonzaga University 
      Hospital, 10043 Orbassano, Italy.
FAU - Napoli, Valerio Maria
AU  - Napoli VM
AD  - Department of Oncology, University of Turin, San Luigi Gonzaga University 
      Hospital, 10043 Orbassano, Italy.
FAU - Bertaglia, Valentina
AU  - Bertaglia V
AD  - Department of Oncology, University of Turin, San Luigi Gonzaga University 
      Hospital, 10043 Orbassano, Italy.
FAU - Bianco, Valentina
AU  - Bianco V
AD  - Department of Oncology, University of Turin, San Luigi Gonzaga University 
      Hospital, 10043 Orbassano, Italy.
FAU - Capelletto, Enrica
AU  - Capelletto E
AD  - Department of Oncology, University of Turin, San Luigi Gonzaga University 
      Hospital, 10043 Orbassano, Italy.
FAU - D'Amiano, Carmen
AU  - D'Amiano C
AD  - Department of Oncology, University of Turin, San Luigi Gonzaga University 
      Hospital, 10043 Orbassano, Italy.
FAU - Di Maio, Massimo
AU  - Di Maio M
AUID- ORCID: 0000-0001-8906-3785
AD  - Department of Oncology, University of Turin, Mauriziano Hospital, 10128 Torino, 
      Italy.
FAU - Gianetta, Martina
AU  - Gianetta M
AD  - Department of Oncology, University of Turin, San Luigi Gonzaga University 
      Hospital, 10043 Orbassano, Italy.
FAU - Novello, Silvia
AU  - Novello S
AD  - Department of Oncology, University of Turin, San Luigi Gonzaga University 
      Hospital, 10043 Orbassano, Italy.
FAU - Passiglia, Francesco
AU  - Passiglia F
AD  - Department of Oncology, University of Turin, San Luigi Gonzaga University 
      Hospital, 10043 Orbassano, Italy.
FAU - Scagliotti, Giorgio Vittorio
AU  - Scagliotti GV
AUID- ORCID: 0000-0001-6646-958X
AD  - Department of Oncology, University of Turin, San Luigi Gonzaga University 
      Hospital, 10043 Orbassano, Italy.
FAU - Bironzo, Paolo
AU  - Bironzo P
AD  - Department of Oncology, University of Turin, San Luigi Gonzaga University 
      Hospital, 10043 Orbassano, Italy.
LA  - eng
PT  - Journal Article
DEP - 20230109
PL  - Switzerland
TA  - Biomedicines
JT  - Biomedicines
JID - 101691304
PMC - PMC9855735
OTO - NOTNLM
OT  - COVID-19 pandemic
OT  - COVID-19 vaccination
OT  - SARS-CoV-2 infection
OT  - cancer patients
OT  - patients reported outcomes
OT  - prevention strategies
OT  - thoracic malignancies
COIS- Paolo Bironzo received honoraria and had roles as a consultant and advisor for 
      AstraZeneca, Bristol Myers Squibb, MSD Oncology, BeiGene, Roche, and Takeda and 
      received an institutional research grant (not related to the present work) from 
      Pfizer and a travel grant from Amgen; Enrica Capelletto had roles as a consultant 
      or advisor for AstraZeneca, MSD, and Boehringer Ingelheim; Massimo Di Maio 
      received honoraria and had roles as a consultant or advisor for AstraZeneca, 
      Pfizer, Novartis, Roche, Eisai, Janssen, Astellas, Boehringer Ingelheim, Merck 
      Sharp & Dohme and received an institutional research grant by 
      Tesaro-GlaxoSmithKline, outside this work; Francesco Passiglia had roles as a 
      consultant or advisor for AstraZeneca, MSD Oncology, Amgen and received a travel 
      grant from MSD Oncology and Roche; Silvia Novello received honoraria and had 
      roles as a consultant or advisor for AstraZeneca, Amgen, Eli Lilly, Beigene, 
      Boehringer Ingelheim, MSD, Roche, Takeda, Pfizer, Novartis, and Sanofi; Giorgio 
      Vittorio Scagliotti received honoraria and had roles as a consultant or advisor 
      for AstraZeneca, Eli Lilly, Beigene, MSD, Roche, Takeda, Pfizer, Johnson & 
      Johnson, Verastem, and Tesaro. No other potential conflicts of interest were 
      reported.
EDAT- 2023/01/22 06:00
MHDA- 2023/01/22 06:01
PMCR- 2023/01/09
CRDT- 2023/01/21 01:14
PHST- 2022/11/26 00:00 [received]
PHST- 2022/12/23 00:00 [revised]
PHST- 2023/01/06 00:00 [accepted]
PHST- 2023/01/21 01:14 [entrez]
PHST- 2023/01/22 06:00 [pubmed]
PHST- 2023/01/22 06:01 [medline]
PHST- 2023/01/09 00:00 [pmc-release]
AID - biomedicines11010165 [pii]
AID - biomedicines-11-00165 [pii]
AID - 10.3390/biomedicines11010165 [doi]
PST - epublish
SO  - Biomedicines. 2023 Jan 9;11(1):165. doi: 10.3390/biomedicines11010165.